Hyperion Defi, Inc.
HYPD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001682639
No open-market purchases or sales by Hyperion Defi, Inc. insiders were filed in the last 90 days; 33 institutions reported holding it in 13F filings for Q2 2026, worth $7.92M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Hyperion Defi, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Hyperion Defi, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Jung Hyunsu | See Remarks | 1,345,676 | Aug 18, 2026 | 4 |
| Walters Happy David | Director | 170,847 | Jul 1, 2026 | 2 |
| Strahlman Ellen R | Director | 150,078 | Jul 1, 2026 | 3 |
| Jacobson Rachel | Director | 115,218 | Jul 1, 2026 | 1 |
| Geltzeiler Michael S | Director | 146,932 | Jul 1, 2026 | 2 |
| Knox David R. | Chief Financial Officer | 307,119 | Apr 1, 2026 | 3 |
| Rubenstein Robert | General Counsel | 75,000 | Jan 12, 2026 | 1 |
| Rowe Michael M | Chief Executive Officer | 7,975 | Jul 9, 2025 | 0 |
| Lasry Marc | 10% Owner | – | Jun 3, 2025 | 0 |
| Avenue Capital Management II, L.P. | 10% Owner | – | Jun 3, 2025 | 0 |
| Avenue Venture Opportunities Fund, L.P. | 10% Owner | – | Jun 3, 2025 | 0 |
| Avenue Venture Opportunities Fund II, L.P. | 10% Owner | – | Jun 3, 2025 | 0 |
| Mather Charles E IV | Director | 9,950 | Apr 29, 2025 | 0 |
| Ianchulev Tsontcho | Director | 10,122 | Apr 29, 2025 | 0 |
| Palanki Ram | Director | 4,235 | Apr 29, 2025 | 0 |
| Kern Bren | Chief Operating Officer | 50,031 | Apr 23, 2025 | 0 |
| Jones Andrew D. | Chief Financial Officer | – | Sep 3, 2024 | 0 |
| Grant Stuart M. | 10% Owner | 10,914,153 | Jul 3, 2024 | 0 |
| Gandolfo John P | Chief Financial Officer | 8,000 | Feb 14, 2024 | 0 |
| Benjamin Stephen Keith | Director | 3,289 | Jun 29, 2022 | 0 |
| Lee Kenneth B Jr | Director | 64,544 | Jun 21, 2022 | 0 |
| Haller Julia A | Director | 30,408 | Jun 21, 2022 | 0 |
| Eshelman Fredric N | Director | 1,299,750 | Nov 22, 2021 | 0 |
| Mario Ernest | Director | 382,706 | Nov 22, 2021 | 0 |
| Sun Anthony Y | Director | 26,322 | Nov 22, 2021 | 0 |
| LaBelle Curt H | Director | 42,236 | Nov 22, 2021 | 0 |
| Clasby Jennifer G | VP, Regulatory and Clinical | 66,537 | Jul 21, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2025 (view filing) | Dec 26-29 | 4 days | Strahlman Ellen RDirector | PPurchaseCommon Stock, par value $.0001 | +15.7K | $3.66 | +$57.5K | +20.8%91.2K after | 2 lots |
| Dec 30, 2025 (view filing) | Dec 26-29 | 4 days | Strahlman Ellen RDirector | PPurchaseCommon Stock, par value $.0001 | +15.2K | $3.66 | +$55.6K | +77.0%34.9K after | 2 lots |
| Jan 5, 2026 (view filing) | Dec 31, 2025 | 5 days | Knox David R.Chief Financial Officer | PPurchaseCommon Stock, par value $0.0001 | +27.9K | $3.59 | +$100.3K | +9.3%327.9K after | |
| Jun 2, 2026 (view filing) | Jun 1-2 | 1 day | Jung HyunsuSee Remarks | PPurchaseCommon Stock, par value $0.0001 | +8.00K | $3.70 | +$29.6K | +0.6%1.39M after | 4 lots |